Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) Tax Provisions: 2021-2022

  • Cartesian Therapeutics' Tax Provisions fell 308.70% to -$288,000 in Q4 2022 from the same period last year, while for Dec 2022 it was $15.4 million, marking a year-over-year change of. This contributed to the annual value of $287,000 for FY2024, which is 101.51% up from last year.
  • Cartesian Therapeutics' Tax Provisions amounted to -$288,000 in Q4 2022, which was up 10.28% from -$321,000 recorded in Q3 2022.
  • In the past 5 years, Cartesian Therapeutics' Tax Provisions ranged from a high of $15.8 million in Q3 2021 and a low of -$321,000 during Q3 2022.
  • For the 2-year period, Cartesian Therapeutics' Tax Provisions averaged around $3.8 million, with its median value being -$75,000 (2021).
  • Data for Cartesian Therapeutics' Tax Provisions shows a maximum YoY crashed of 308.70% (in 2022) over the last 5 years.
  • Quarterly analysis of 2 years shows Cartesian Therapeutics' Tax Provisions stood at $138,000 in 2021, then slumped by 308.70% to -$288,000 in 2022.
  • Its Tax Provisions was -$288,000 in Q4 2022, compared to -$321,000 in Q3 2022 and $138,000 in Q4 2021.